What are the key arguments against uric acid as a true risk factor for hypertension?

Hypertension

Volumn 61, Issue 5, 2013, Pages 948-951

  Johnson, Richard J ^a   Sánchez Lozada, Laura G ^b   Mazzali, Marilda ^c   Feig, Daniel I ^d   Kanbay, Mehmet ^e   Sautin, Yuri Y ^f  

^a UNIVERSITY OF COLORADO   (United States)

^b Laboratory of Renal Physiopathology and Department of Nephrology   (Mexico)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^f UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORTALIDONE; PEROXYNITRITE; PURINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; URIC ACID; XANTHINE OXIDASE;

ARTICLE; CARDIOVASCULAR RISK; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; HYPERURICEMIA; PRIORITY JOURNAL; PURINE METABOLISM; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY; RISK FACTORS; URIC ACID;

EID: 84876689726     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00650     Document Type: Article

References (50)

1. Feig D, Madero M, Jalal D, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origins of hypertension. J Peds. 2012;in press.
2. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355-360.
3. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247-252.
4. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924-932.
5. Soletsky B, Feig DI. Uric acid reduction rectifes prehypertension in obese adolescents. Hypertension. 2012;60:1148-1156.
6. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, Johnson RJ. A randomized study of allopurinol on endothe-lial function and estimated glomular fltration rate in asymptomatic hyper-uricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6:1887-1894.
7. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and protein-uria in patients with normal renal functions. Int Urol Nephrol. 2007;39: 1227-1233.
8. Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial infammation in salt-sensitive hypertension. Hypertens Res. 2010;33:975-980.
9. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78: 6858-6862.
10. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235:747-754.
11. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, Harrison DG, Fukai T. Peroxidase properties of extracellular superox-ide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002;22:1402-1408.
12. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol. 2005;70:343-354.
13. Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SR. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci. 2003;105:425-430.
14. Waring WS, McKnight JA, Webb DJ, Maxwell SR. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes. 2006;55:3127-3132.
15. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131-139.
16. Reyes AJ, Leary WP. The increase in serum uric acid induced by diuretics could be benefcial to cardiovascular prognosis in hypertension: a hypothesis. J Hypertens. 2003;21:1775-1777.
17. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA. 1998;95:675-680.
18. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-2516.
19. Caulfeld MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5:e197.
20. Yang Q, Köttgen A, Dehghan A, et al. Multiple genetic loci infuence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3:523-530.
21. Köttgen A, Albrecht E, Teumer A, et al; LifeLines Cohort Study; CARDIoGRAM Consortium; DIAGRAM Consortium; ICBP Consortium; MAGIC Consortium. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45:145-154.
22. Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28:1234-1242.
23. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and-independent fatty liver. J Biol Chem. 2012;287:40732-40744.
24. Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH, Johnson RJ. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121:e71-e78.
25. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate effux transporter URATv1 (SLC2A9) in humans. J Biol Chem. 2008;283:26834-26838.
26. Bibert S, Hess SK, Firsov D, Thorens B, Geering K, Horisberger JD, Bonny O. Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol. 2009;297:F612-F619.
27. Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.
28. Hershfeld MS, Roberts LJ 2nd, Ganson NJ, Kelly SJ, Santisteban I, Scarlett E, Jaggers D, Sundy JS. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA. 2010;107:14351-14356.
29. Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, Johnson RJ, Henderson GN. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids. 2009;28:118-149.
30. Imaram W, Gersch C, Kim KM, Johnson RJ, Henderson GN, Angerhofer A. Radicals in the reaction between peroxynitrite and uric acid identifed by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med. 2010;49:275-281.
31. Gonsette RE, Sindic C, D'hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D; ASIIMS study group. Boosting endog enous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing-remitting Multiple Sclerosis (ASIIMS) trial. Mult Scler. 2010;16:455-462.
32. Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H. The treatment of multiple sclerosis with inosine. J Altern Complement Med. 2009;15:619-625.
33. Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D'Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G. Increase of uric acid and purine compounds in biological fuids of multiple sclerosis patients. Clin Biochem. 2009;42: 1001-1006.
34. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a patho-genetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-1190.
35. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1:16.
36. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106.
37. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-F997.
38. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor β and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435-440.
39. Roncal CA, Reungjui S, Sánchez-Lozada LG, Mu W, Sautin YY, Nakagawa T, Johnson RJ. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome. Am J Nephrol. 2009;30:399-404.
40. Cirillo P, Gersch MS, Mu W, Scherer PM, Kim KM, Gesualdo L, Henderson GN, Johnson RJ, Sautin YY. Ketohexokinase-dependent metabolism of fructose induces proinfammatory mediators in proximal tubular cells. J Am Soc Nephrol. 2009;20:545-553.
41. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS ONE. 2012;7:e47948.
42. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol, Cell Physiol. 2007;293:C584-C596.
43. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY. Hyperuricemia as a mediator of the proinfammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258-1269.
44. Lanaspa M, Sautin Y, Ejaz A, Madero M, Le M, Manitius J, Sanchez-Lozada LG, Nakagawa T, Johnson RJ. Uric acid and metabolic syndrome: what is the relationship? Curr Rheum Rev. 2011;7:162-169.
45. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285:17271-17276.
46. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. Therapeutic targeting of mitochon-drial superoxide in hypertension. Circ Res. 2010;107:106-116.
47. Rodríguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol. 2004;286:F606-F616.
48. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460.
49. Harrison DG, Vinh A, Lob H, Madhur MS. Role of the adaptive immune system in hypertension. Curr Opin Pharmacol. 2010;10:203-207.
50. Pons H, Ferrebuz A, Quiroz Y, Romero-Vasquez F, Parra G, Johnson RJ, Rodriguez-Iturbe B. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am J Physiol Renal Physiol. 2013;304:F289-F299.